CooperVision, CORE Share Insights from Myopia Clinical Trial at GCOMM 2019 Conference

Tuesday, June 4 2019 | 21 h 07 min | News

Eye care professionals and researchers from Canada and around the world will gather at the Global Council on Myopia Management’s 2019 Conference June 7 and 8, 2019. CooperVision, as well as Paragon Vision Sciences, a member of CooperVision’s Specialty Eye Care Division, will be on site championing the best way to manage myopia progression and improve treatment of the condition.

Dr. Jill Woods, Research Manager and Senior Clinical Scientist at the Centre for Ocular Research and Education (CORE), will be sharing four-year results from CooperVision’s landmark MiSight^® 1 day myopia management clinical trial during her breakout session on Saturday, June 8 at 1:00 p.m.

“Myopia is affecting children at a much younger age, causing them to have a much higher prescription in their teen and adult years. This can lead to serious eye conditions down the road,” said Woods. “The MiSight^® 1 day clinical trial illustrates the benefits of beginning myopia management early and shows how a contact lens management solution can maximize the benefit to the child.”

The clinical trial has shown the significant impact of a contact lens management approach to slowing the progression of myopia in children. After year three, myopia progression slowed in children wearing the MiSight^® 1 day contact lens: 59% as measured by mean cycloplegic spherical equivalent (SE) and 52% as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision 1-day contact lens.

Blanchard Contact Lenses, another member of CooperVision’s Specialty Eye Care Division, will also be at GCOMM promoting its scleral contact lenses designed to treat a variety of eye conditions.

Click HERE for the full press release.